	US 12,280,028 B2
	Methods and compositions to inhibit dependence on opioids
Jacqueline M. Iversen, Lloyd Harbor, NY (US); and Thomas A. Dahl, Guilford, CT (US)
Assigned to SEN-JAM PHARMACEUTICAL INC., Huntington, NY (US)
Filed by SEN-JAM PHARMACEUTICAL INC., Huntington, NY (US)
Filed on Mar. 29, 2021, as Appl. No. 17/216,157.
Application 17/216,157 is a continuation of application No. 16/896,928, filed on Jun. 9, 2020, abandoned.
Application 16/896,928 is a continuation of application No. 16/133,458, filed on Sep. 17, 2018, granted, now 10,675,261, issued on Jun. 9, 2020.
Claims priority of provisional application 62/560,046, filed on Sep. 18, 2017.
Prior Publication US 2021/0212971 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/192 (2006.01); A61K 9/00 (2006.01); A61K 9/68 (2006.01); A61P 25/36 (2006.01); A61K 31/4535 (2006.01)

CPC A61K 31/192 (2013.01) [A61K 9/0056 (2013.01); A61K 9/0058 (2013.01); A61P 25/36 (2018.01); A61K 31/4535 (2013.01); A61K 2300/00 (2013.01)]

12 Claims

1. A method of inhibiting dependence to an opioid by a human subject in need thereof, comprising:

administering an effective amount of a pharmaceutical composition to the subject during opioid therapy,

wherein the pharmaceutical composition comprises:

a) a non-steroidal anti-inflammatory drug (NSAID); and

b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof;

wherein dependence to an opioid is inhibited in the human subject.